Clinical Trials | November 13, 2025
Philogen updates on Fibromun clinical study developments
FIBROSARC did not meet its primary PFS endpoint in the final analysi
FIBROSARC did not meet its primary PFS endpoint in the final analysi
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
This partnership has led to a 10% boost in delivery speed
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Subscribe To Our Newsletter & Stay Updated
